Journal of the National Cancer Institute最新文献

{"title":"Association of a major tobacco tax increase in California with increased smoking cessation","authors":"Shu-Hong Zhu, Christopher M Anderson, Yue-Lin Zhuang, Hai-Yen Sung, Anthony C Gamst","doi":"10.1093/jnci/djaf121","DOIUrl":"https://doi.org/10.1093/jnci/djaf121","url":null,"abstract":"Background In November 2016, California voters approved Proposition 56, increasing the cigarette tax by $2.00 per pack and nearly tripling spending on tobacco prevention. This study examined whether the initiative was associated with increased smoking cessation. Methods States in the United States were categorized into 3 groups: California, 18 other states (including the District of Columbia) that raised taxes, and 32 states that did not raise taxes. Tax and price increases, tobacco prevention spending per capita, 3-month smoking cessation rates using data from the Behavioral Risk Factor Surveillance System (N = 443 054), and the proportion of daily smoking were compared for 2014-2016 and 2017-2019 for these groups. Results California had the largest increases in cigarette price (30.8%) and tobacco prevention spending (271.9%), both adjusted for inflation. Other states that raised taxes experienced price increases of 6.3% on average. The 3-month smoking cessation rate in California increased from 11.5% in 2014-2016 to 14.2% in 2017-2019 (P = .005). Among other states that raised taxes in that timeframe, cessation rates did not change significantly, from 8.6% to 8.7% (P = .755). Among states that did not raise taxes, cessation rates declined significantly, from 9.5% to 9.0% (P = .026). California also had a significant reduction in the proportion of daily smokers among those who did not quit (from 60.4% to 56.4%, P = .012). Conclusions A major cigarette tax increase was associated with increased smoking cessation in California. Policies increasing tobacco taxes and re-investing new revenue in tobacco prevention can increase population cessation.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144500626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Cancer Predisposition Screening Tool for Young Adults with Cancer.","authors":"Tim Ripperger,Christian P Kratz","doi":"10.1093/jnci/djaf150","DOIUrl":"https://doi.org/10.1093/jnci/djaf150","url":null,"abstract":"One in twelve malignancies is diagnosed in a young adult between 20 and 39 years of age. One of the most relevant known causes of cancer in this age group, which is present in approximately 10% of cancer patients, is genetic cancer predisposition that originates from constitutional or postzygotic somatic (epi-)genetic variants leading to an increased cancer risk compared to the general population. The diagnosis of a cancer predisposition syndrome is important as it can affect cancer surveillance, prevention, and therapy. Universal gene-panel germline sequencing is offered by some centers, however, in clinical settings with limited resources, cancer predisposition syndrome screening tools can support the identification of those cancer patients who may benefit from genetic counselling and/or testing regarding underlying genetic diseases. Effective screening tools have been developed for children with cancer, but comparable cancer predisposition syndrome screening algorithms are lacking for young adults with cancer. We present here an easy-to-use cancer predisposition syndrome screening tool designed specifically for young adults with cancer. By combining available recommendations and disease-specific criteria, the algorithm is focusing on somatic genetic findings in malignant cells, specific cancer types strongly associated with cancer predisposition syndromes, and the personal and family past medical history. This tool may increase clinical awareness among oncologists and facilitate the diagnoses of cancer predisposition syndromes in young adults with cancer.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stepped-care models for cancer symptom management: A systematic review of efficacy and cost-effectiveness.","authors":"Tasnim Abdalla,Gursharan K Singh,Shiva Pouraliroudbaneh,Dorcas Serwaa,Michelle Peate","doi":"10.1093/jnci/djaf153","DOIUrl":"https://doi.org/10.1093/jnci/djaf153","url":null,"abstract":"BACKGROUNDThe delivery of clinical care services using personalised health approaches is an integral component of cancer care. This review synthesised evidence on the efficacy and cost-effectiveness of stepped-care interventions delivered to manage therapy-related symptoms in cancer populations compared to care-as-usual (CAU).METHODSSystematic searches were conducted in MEDLINE, PsycINFO, Embase, Web of Science, Cochrane Library, National Health Service Economic Evaluation Database, and EconLit to identify studies published from Jan 2010 to Nov 2024. Peer-reviewed studies that reported outcomes of stepped interventions and CAU were included, and quality appraisal was performed using the Cochrane Risk of Bias 2 and the Risk of Bias In Non-Randomised Studies-of Interventions tools.RESULTSThe review summarises a total of 22 studies, involving 4,588 unique adult cancer survivors. Fourteen studies identified statistically significant improvements in symptom severity and clinical outcomes comparable to those of CAU. The stepped-care group showed reduced mean severity scores for distress, insomnia and fatigue, as well as improved stress reactions and emotional reactivity, and fewer palliative care visits. The Low uptake of the intervention and inadequate assessment of comorbid symptoms have hindered the ability to draw conclusive recommendations across several studies. Four studies reported cost-effectiveness evidence, which showed cost savings of approximately €19,991 for each point improvement on the distress scale and lower incremental costs of approximately €3,950 associated with stepped-care interventions.CONCLUSIONSThis review highlights the potential clinical and economic benefits of implementing stepped-care interventions to reduce the severity of cancer-related symptoms. Further research is warranted to determine the long-term effectiveness and sustainability of stepped-care interventions in representative cancer populations and routine clinical care settings.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144488095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enrollment in children’s oncology group’s clinical trials: population-based linkage with the national childhood cancer registry","authors":"Philip J Lupo, David A Siegel, Nicola C Schussler, Todd A Alonzo, Suzanne Adams, David Angelaszek, Shanthala Basavappa, Tiffany M Chambers, Linda Coyle, Eric Durbin, Johanna L Goderre, Tiffany Hayes, Will Howe, Elizabeth Hsu, Richard Lee, Denise R Lewis, Angela B Mariotto, Brad H Pollock, Anca Preda, Michael E Roth, Jennifer Stevens, Tina Terranova, Sarah L Vargas, Douglas S Hawkins, Lynne Penberthy","doi":"10.1093/jnci/djaf134","DOIUrl":"https://doi.org/10.1093/jnci/djaf134","url":null,"abstract":"Background Improvements in outcomes among children and adolescents diagnosed with cancer are attributable to many factors—including clinical trials such as those administered through the Children’s Oncology Group (COG), as well as population-based resources like the National Childhood Cancer Registry (NCCR). The objective of this study was to link COG trial data with the NCCR to evaluate overall enrollment patterns. Methods Data were received from the NCCR and COG, which were linked using an array of variables and then compared to evaluate enrollment patterns in COG studies from 2007-2018. Multivariable logistic regression was used to identify characteristics associated with not being enrolled in a COG study. Results Among 134,696 NCCR cancer patients, 51,062 matched with COG study enrollees. There were several differences in demographic and clinical characteristics between those enrolled and not enrolled in COG studies. Enrollment was higher among children aged 0-4 years compared to adolescents aged 15-19 years (53.7% vs 20.1%). Differences by race/ethnicity were also observed; for example, those who identified as non-Hispanic White were more likely to be enrolled than those who identified as non-Hispanic Asian/Pacific Islander (38.8% vs 32.9%). In a multivariable logistic regression model, several characteristics were significantly associated with not being enrolled in a COG study, including age at diagnosis, year of diagnosis, race/ethnicity, and cancer type. Conclusion Our results suggest that several groups are underrepresented in COG clinical trials. This information can help guide the prioritization of population groups for engagement in future studies.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144288374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary evidence-based consensus statements on salvage surgery for recurrent head and neck cancer (International Centre for Recurrent head and neck Cancer)","authors":"Andrew Williamson, Grainne Brady, Natalie Harris, Puteri Abdul Haris, Brian Bisase, Kevin Chiu, Catriona Douglas, Jason Fleming, David Hamilton, Anoop Haridass, Ceri Hughes, Muhammad Shahid Iqbal, Cyrus Kerawala, Emma King, Ziwei Liu, James McCaul, Jenny Montgomery, Paul Nankivell, Iain Nixon, David Noble, Michael Nugent, Claire Paterson, Paul Pracy, Francesco Riva, Justin Roe, Andrew Schache, Uthaya Selbong, Clare Schilling, Ricard Simo, Stuart Winter, Ben O’Leary, Vinidh Paleri","doi":"10.1093/jnci/djaf128","DOIUrl":"https://doi.org/10.1093/jnci/djaf128","url":null,"abstract":"Background Recurrent head and neck squamous cell carcinomas (rHNSCC) are an understudied subgroup, lacking high quality evidence and thus gold standard management recommendations, resulting in significant variations in practice. The aim of this project was to deliver a national multi-disciplinary expert consensus on patients with rHNSCC managed by curative salvage surgery. Methods The AGREEII protocol guided the Delphi process. Best practice statements were developed after literature review on the perioperative management and surgical salvage of major rHNSCC subsites. Members of the International centre for Recurrent head and neck cancer (IREC) network, and other UK based professional stakeholder organisations were invited into an online Delphi study. Participants voted upon statements over three rounds, with items modified in response to vote thresholds and comments. Results Twenty-eight experts participated including 11 otolaryngologists, 7 oncologists, 9 oral and maxillofacial surgeons, and 1 speech and language therapist. Consensus was achieved on 73 statements, with 29 (39.7%) achieving unanimous (threshold: 100%) and 25 (34.2%) (threshold >90%) agreement. Conclusions Salvage surgery for rHNSCC are challenging cases that require intensive multidisciplinary input to achieve cure while balancing impact on function and quality-of-life. In this article, we provide a large series of statements based on UK-wide expert consensus, that will guide clinicians through the complex intra- and perioperative management of patients undergoing surgical salvage.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144288375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma","authors":"Fergus Keane, Lily V Saadat, Catherine A O’Connor, Joanne F Chou, Anita S Bowman, Fei Xu, Fionnuala Crowley, Neha Debnath, Joshua D Schoenfeld, Anupriya Singhal, Drew Moss, Darren Cowzer, Emily Harrold, Wungki Park, Anna Varghese, Fiyinfolu Balogun, Kenneth H Yu, Alice Zervoudakis, Marinela Capanu, Michael F Berger, Alice C Wei, Angela Rose Brannon, Eileen M O’Reilly","doi":"10.1093/jnci/djaf139","DOIUrl":"https://doi.org/10.1093/jnci/djaf139","url":null,"abstract":"Importance The utility of ctDNA in addressing challenges of molecular tissue profiling and complementing NGS is undefined in pancreas ductal adenocarcinoma (PDAC). Objective To assess ctDNA detection rates by stage, disease burden, metastasis patterns, compare overall survival (OS) between ctDNA-positive and ctDNA-negative cases, and determine concordance between ctDNA and matched-tissue biopsies. Design Single-institution study, 2019- 2022. Setting Memorial Sloan Kettering. Participants Patients with PDAC and ctDNA profiling. Main Outcomes and Measures Clinical, survival data abstracted from medical records. NGS by MSK-ACCESS ctDNA assay. Results Four hundred and fourteen patients with PDAC: 28% stage I/II, 21% stage III, 51% stage IV. ctDNA detection highest among patients with advanced disease: 75% stage IV, 38% stage III, 34% stage I/II disease. For stage IV, ctDNA more frequently detected with ≥2 organs involved than with <2 organs (76% vs 38%, P = .025). Higher rates ctDNA detection observed in patients with liver metastases vs without (82% vs 52%, P < .001). In untreated stage IV cohort (N = 120), median OS was 10 months for those with detectable ctDNA (95% CI 6.9, 14) vs 19 months (95% CI 13, Not Reached) for those with undetectable ctDNA (P = .1). Concordance between ctDNA and matched tissue NGS lower in untreated stage I-III disease, but high for untreated stage IV PDAC, including critical success index of 93.1% of KRAS variants. Conclusion ctDNA is a promising tool in detection of somatic variants in PDAC. Concordance between ctDNA and tissue is high for patients with untreated metastatic disease, notably for detection of KRAS variants.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual health outcomes after colorectal cancer diagnosis in females: a population-based cohort study","authors":"Niki Oveisi, Eric C Sayre, Lori A Brotto, Vicki Cheng, Vienna Cheng, Sharlene Gill, Gillian E Hanley, Helen McTaggart-Cowan, Stuart Peacock, Meera Rayar, Amirrtha Srikanthan, Dani Taylor, Mikaela Barnes, Mary A De Vera","doi":"10.1093/jnci/djaf120","DOIUrl":"https://doi.org/10.1093/jnci/djaf120","url":null,"abstract":"Background Colorectal cancer (CRC) affects a growing number of females. Our objective was to evaluate the impact of CRC on sexual health outcomes among females, while controlling for age. Methods We conducted a cohort study using administrative health data from the province of British Columbia (BC) including linked health visits and cancer registry from 1985–2017. The cohort included females with CRC (n = 25,402; mean age (SD): 69.0 (13.1)) and matched controls without cancer (n = 254,020; 69.0 (13.1)) in a 1:10 ratio by age, further stratified by age groups (≤39 years and ≥40 years). Multivariable Cox regression models assessed the associations between CRC and five sexual health outcomes (dyspareunia, pelvic inflammatory disease, endometriosis, abnormal bleeding, and premature ovarian failure), adjusting for covariates. Sensitivity analyses focused on females with CRC to explore associations between sociodemographic and cancer-related factors and sexual health outcomes. Tests were 2-sided (statistical significance p-value < 0.05). Results Females with CRC had higher risks of dyspareunia (HR 1.67; 95% CI 1.62–1.73), pelvic inflammatory disease (HR 3.42; 95% CI: 3.07–3.81), and endometriosis (HR 1.95; 95% CI: 1.69 –2.25) compared to controls. In the ≥40-year group, these associations persisted, while in the ≤39-year group, endometriosis was not associated with CRC, but premature ovarian failure was (HR 1.75; 95% CI: 1.40–2.19). In sensitivity analyses, we also observed associations with cancer treatments (surgery, chemotherapy, radiation) and sexual health outcomes. Conclusions This population-based study identified associations between CRC and adverse sexual health outcomes among female patients, highlighting the need for targeted interventions and support.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"182 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of atherosclerotic cardiovascular disease after cancer diagnosis: findings from three prospective cohort studies","authors":"Qiang Liu, Qiaoli Wang, Kai Wang, Han Han, Molin Wang, Jing Wang, Mingyang Song, Edward Giovannucci","doi":"10.1093/jnci/djaf122","DOIUrl":"https://doi.org/10.1093/jnci/djaf122","url":null,"abstract":"Background To determine the association between cancer diagnosis and subsequent risk of ASCVD, and to examine the trajectory of the association over time after cancer diagnosis. Methods We prospectively followed 108,689 women in the Nurses’ Health Study (NHS) (1984-2020), 113,569 women in the NHSII (1991-2019), and 45,328 men in the Health Professionals Follow-up Study (HPFS) (1986-2016) who were free of ASCVD and cancer at baseline. We conducted multivariable-adjusted time-varying Cox proportional hazards regression models to assess ASCVD risk following individual cancer diagnosis. Results During up to 36 years of follow-up, 4,334 new-onset ASCVD events among 49,603 incident cancer cases were documented. After adjusting for shared risk factors, cervical cancer (HR: 1.56; 95%CI: 1.06-2.29) and Hodgkin lymphoma (HR: 2.80; 95%CI: 1.89-4.15) was associated with increased risk of ASCVD incidence, while prostate cancer was associated with a lower ASCVD incidence (HR: 0.91; 95% CI: 0.85-0.97). Compared to cancer-free individuals, breast cancer survivors experienced lower ASCVD risk during the first 7.5 years but gradually increased afterwards (Pnon-linearity=0.01). The risk of ASCVD increased over time among patients with cancers of the colorectum (P = .003), lung (P = .002), and endometrium (P = .04). No significant association with ASCVD risk was observed for cancers of the oral cavity and pharynx, sarcoma, melanoma, kidney, thyroid, leukemia, or ovary. Conclusions Cervical cancer or Hodgkin lymphoma was associated with an increased risk of new-onset ASCVD, independent of shared risk factors, while no increased risk was found with other cancers. ASCVD risk trajectories varied over time after diagnosis according to cancer types.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of aggressive prostate cancer with successive generations in the U.S. among Latino men","authors":"Fei Chen, Adelynn Paik, Xin Sheng, Iona Cheng, Salma Shariff-Marco, Lynne R Wilkens, Loïc Le Marchand, David V Conti, Christopher A Haiman, Veronica Wendy Setiawan","doi":"10.1093/jnci/djaf119","DOIUrl":"https://doi.org/10.1093/jnci/djaf119","url":null,"abstract":"Background US-born Latino men have a higher incidence of prostate cancer (PCa) than foreign-born Latino men. It was not clear whether these increases were exclusively due to increased detection of PCa in the US, changes in risk factors of PCa, or a combination of both. Methods In the Multiethnic Cohort (MEC) we evaluated the association between generational status and risk of PCa in 19,597 Latino men, adjusting for demographic and lifestyle factors, individual- and neighborhood-level socioeconomic status (SES), as well as history of PSA screening. Additional adjustments on polygenic risk score (PRS) and genetic ancestry were included in the sensitivity analysis in the biorepository cohort with genetic data. Results This analysis included 10,241 1st-generation, 4,610 2nd-generation, and 4,746 3rd-generation Latino men, among whom 2,366 PCa were diagnosed during an average of 19.2 years of follow-up. After adjusting for covariates, we observed no association between generational status and risk of overall, localized, or low-grade PCa. A per generation increase was significantly associated with a 13% to 15% elevated risk of high-grade, advanced, or aggressive PCa. These associations with aggressive forms of PCa remained significant in the biorepository cohort with additional adjustment on PRS and genetic ancestry. Conclusions Successive generations in the US were associated with an increased risk of aggressive forms of PCa among Latino men and the observed increases cannot be explained by differences in genetic susceptibility, ancestry, PSA screening, lifestyle, and SES factors. Further investigations are needed to identify additional factors that contribute to this increased risk.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assisted reproductive technology utilization for cancer survivors: how we can do better.","authors":"Erin Hupy,Zaraq Khan,Alessandra J Ainsworth,Chandra C Paff Shenoy","doi":"10.1093/jnci/djaf101","DOIUrl":"https://doi.org/10.1093/jnci/djaf101","url":null,"abstract":"","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}